Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.

AIM To investigate the relationship of urokinase type plasminogen activator receptor (uPAR) and vascular endothelial growth factor (VEGF) expression with clinical and pathological characteristics of human gallbladder cancer. METHODS uPAR and VEGF expressions in 68 gallbladder cancer tissues were detected with anti-receptor immunohistochemical stain. RESULTS Expression rate of uPAR was 57.4% (39/68), and VEGF 51.5% (35/68) in gallbladder cancer tissues. Expression of both uPAR and VEGF was significantly related to metastasis, but not significantly correlated with differentiation stage and size of gallbladder cancer. CONCLUSION Expression of uPAR and VEGF may be an invasive phenotype of gallbladder cancer and indicator for predicting prognoses, and uPAR expression is significantly correlated with the expression of VEGF.

[1]  C. D. de Bock,et al.  Clinical significance of urokinase‐type plasminogen activator receptor (uPAR) expression in cancer , 2004, Medicinal research reviews.

[2]  N. Brünner,et al.  Comparative evaluation of urokinase‐type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells , 2003, International journal of cancer.

[3]  M. Perricaudet,et al.  In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy , 2003, Gene Therapy.

[4]  F. Blasi,et al.  Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions , 2003, The EMBO journal.

[5]  W. Hornebeck,et al.  Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. , 2003, Experimental cell research.

[6]  D. Sliva,et al.  Aspirin inhibits highly invasive prostate cancer cells. , 2003, International journal of oncology.

[7]  N. Mitsiades,et al.  Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas , 2003 .

[8]  J. G. van den Berg,et al.  Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection. , 2003, Kidney international.

[9]  W. Folk,et al.  Formation of Polyomavirus-Like Particles with Different VP1 Molecules That Bind the Urokinase Plasminogen Activator Receptor , 2003, Journal of Virology.

[10]  Qifeng Yang,et al.  Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Yu-feng Yuan,et al.  [Relationship of hypoxia-inducible factor 1 alpha (HIF-1alpha) gene expression with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in human colorectal adenoma and adenocarcinoma]. , 2003, Ai zheng = Aizheng = Chinese journal of cancer.

[12]  T. Ng,et al.  Transcriptional regulation of fosl-1 by licorice in rat Clone 9 cells. , 2003, Life sciences.

[13]  Jason L. Townson,et al.  The role of apoptosis in tumor progression and metastasis. , 2003, Current molecular medicine.

[14]  R. Castellon,et al.  ACE inhibition actively promotes cell survival by altering gene expression. , 2003, Biochemical and biophysical research communications.

[15]  D. Tan,et al.  Evaluation of urinary plasminogen activator, its receptor, matrix metalloproteinase-9, and von Willebrand factor in pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  T. Ching,et al.  Distinct ligand binding sites in integrin α3β1 regulate matrix adhesion and cell–cell contact , 2003, The Journal of cell biology.

[17]  R. Mabrouk,et al.  Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma. , 2003, Clinical biochemistry.

[18]  J. Attems,et al.  Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment , 2003, British Journal of Cancer.

[19]  B. Leggett,et al.  Fas ligand and tumour counter‐attack in colorectal cancer stratified according to microsatellite instability status , 2003, The Journal of pathology.

[20]  L. Hofbauer,et al.  Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. , 2003, The Journal of clinical endocrinology and metabolism.

[21]  J. Hoover-Plow,et al.  The role of plasminogen in angiogenesis in vivo , 2003, Journal of thrombosis and haemostasis : JTH.

[22]  G. Giannelli,et al.  Cancer Invasion: Watch Your Neighbourhood! , 2003, Tumori.

[23]  A. Krüger,et al.  Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. , 2003, Current pharmaceutical design.

[24]  C. Mawrin,et al.  Higher susceptibility to Fas ligand induced apoptosis and altered modulation of cell death by tumor necrosis factor-α in periarticular tenocytes from patients with knee joint osteoarthritis , 2003, Arthritis research & therapy.

[25]  R. Caldwell,et al.  VEGF‐induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  C. Berking,et al.  Stroma formation and angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in human skin grafted to SCID mice. , 2003, The Journal of investigative dermatology.

[27]  Hong-chi Jiang,et al.  Current treatment for liver metastases from colorectal cancer. , 2003, World journal of gastroenterology.

[28]  Megumi Baba,et al.  Urokinase‐type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer , 2003, Cancer science.

[29]  M. Marangolo,et al.  A High Cytosol Value of Urokinase-Type Plasminogen Activator (uPA) May Be Predictive of Early Relapse in Primary Breast Cancer , 2003, Cancer investigation.

[30]  P. Bohlen,et al.  Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. , 2002, Current cancer drug targets.

[31]  N. Harbeck,et al.  Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention , 2001, Expert Reviews in Molecular Medicine.

[32]  Megumi Baba,et al.  Urokinase Receptor and Vascular Endothelial Growth Factor Are Synergistically Associated with the Liver Metastasis of Colorectal Cancer , 2001, Japanese journal of cancer research : Gann.

[33]  A. Mazar,et al.  The role of the plasminogen activation system in angiogenesis and metastasis. , 2001, Surgical oncology clinics of North America.

[34]  Yao Wang.  The role and regulation of urokinase‐type plasminogen activator receptor gene expression in cancer invasion and metastasis , 2001, Medicinal research reviews.

[35]  E. Baker,et al.  Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression , 2000, Molecular pathology : MP.

[36]  M. Namiki,et al.  [Correlation between expression of metastasis-related genes and lymph node metastasis in testicular cancer]. , 2000, Hinyokika kiyo. Acta urologica Japonica.

[37]  W. Korte.  Changes of the Coagulation and Fibrinolysis System in Malignancy: Their possible Impact on Future Diagnostic and Therapeutic Procedures , 2000, Clinical chemistry and laboratory medicine.

[38]  H. Watanabe,et al.  Histochemical study of angiogenesis in basaloid squamous carcinoma of the esophagus. , 2000, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[39]  P. Andreasen,et al.  The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.

[40]  V. V. van Hinsbergh,et al.  Aminopeptidase inhibitor bestatin stimulates microvascular endothelial cell invasion in a fibrin matrix , 2003, Thrombosis and Haemostasis.